BACKGROUND: Adipose tissue-derived stem cells (ASCs) have been investigated as therapeutic tools for a variety of autoimmune diseases, including inflammatory diseases. However, the mechanisms underlying the immunomodulatory properties of ASCs are not well understood. Here, we investigated the mechanism of regulatory T cell (Treg) induction in ASC therapy in a murine model of inflammatory bowel disease. METHODS: Acute colitis was induced in mice using dextran sulfate sodium and ASCs administered intraperitoneally. Tregs and CD103+ dendritic cells were analyzed in the mesenteric lymph nodes (MLNs), spleen, and colonic lamina propria (CLP). Activation of latent TGF-β by ASCs was analyzed in vitro using ELISA. siRNA technology was used to create ASCs in which TSP-1 or integrinαv was knocked down in order to investigate the involvement of these proteins in the activation of latent TGF-β. In addition, TSP-1-knockdown ASCs were administered to mice with colitis to assess their clinical efficacy in vivo. RESULTS: Systemic administration of ASCs significantly lessened the clinical and histopathological severity of colitis. ASCs were distributed throughout the lymphatic system in the MLNs and spleen. Tregs were increased in the MLNs and CLP, but CD103+ dendritic cells were not significantly altered. The ASCs activated latent TGF-β. TSP-1 knockdown impaired TGF-β activation in vitro and abrogated the therapeutic effects of the ASCs in vivo. Furthermore, Tregs were not increased in the MLNs and CLP from mice treated with TSP-1-knockdown ASCs. CONCLUSIONS: These results demonstrate that ASCs induce Tregs by activating latent TGF-β via TSP-1, independent of CD103+ dendritic cell induction.
BACKGROUND:Adipose tissue-derived stem cells (ASCs) have been investigated as therapeutic tools for a variety of autoimmune diseases, including inflammatory diseases. However, the mechanisms underlying the immunomodulatory properties of ASCs are not well understood. Here, we investigated the mechanism of regulatory T cell (Treg) induction in ASC therapy in a murine model of inflammatory bowel disease. METHODS: Acute colitis was induced in mice using dextran sulfate sodium and ASCs administered intraperitoneally. Tregs and CD103+ dendritic cells were analyzed in the mesenteric lymph nodes (MLNs), spleen, and colonic lamina propria (CLP). Activation of latent TGF-β by ASCs was analyzed in vitro using ELISA. siRNA technology was used to create ASCs in which TSP-1 or integrinαv was knocked down in order to investigate the involvement of these proteins in the activation of latent TGF-β. In addition, TSP-1-knockdown ASCs were administered to mice with colitis to assess their clinical efficacy in vivo. RESULTS: Systemic administration of ASCs significantly lessened the clinical and histopathological severity of colitis. ASCs were distributed throughout the lymphatic system in the MLNs and spleen. Tregs were increased in the MLNs and CLP, but CD103+ dendritic cells were not significantly altered. The ASCs activated latent TGF-β. TSP-1 knockdown impaired TGF-β activation in vitro and abrogated the therapeutic effects of the ASCs in vivo. Furthermore, Tregs were not increased in the MLNs and CLP from mice treated with TSP-1-knockdown ASCs. CONCLUSIONS: These results demonstrate that ASCs induce Tregs by activating latent TGF-β via TSP-1, independent of CD103+ dendritic cell induction.
Authors: Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes Journal: Gut Date: 2010-10-04 Impact factor: 23.059
Authors: Chao Li; Robert S Flynn; John R Grider; Karnam S Murthy; John M Kellum; Homayoon Akbari; John F Kuemmerle Journal: Inflamm Bowel Dis Date: 2013-12 Impact factor: 5.325
Authors: S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck Journal: Cell Date: 1998-06-26 Impact factor: 41.582
Authors: Morgana T L Castelo-Branco; Igor D P Soares; Daiana V Lopes; Fernanda Buongusto; Cesonia A Martinusso; Alyson do Rosario; Sergio A L Souza; Bianca Gutfilen; Lea Mirian B Fonseca; Celeste Elia; Kalil Madi; Alberto Schanaider; Maria Isabel D Rossi; Heitor S P Souza Journal: PLoS One Date: 2012-03-14 Impact factor: 3.240
Authors: Ana Belén Carrillo-Gálvez; Sheyla Gálvez-Peisl; Juan Elías González-Correa; Marina de Haro-Carrillo; Verónica Ayllón; Pedro Carmona-Sáez; Verónica Ramos-Mejía; Pablo Galindo-Moreno; Francisca E Cara; Sergio Granados-Principal; Pilar Muñoz; Francisco Martin; Per Anderson Journal: Stem Cells Transl Med Date: 2020-02-19 Impact factor: 6.940
Authors: Sirikul Soontararak; Lyndah Chow; Valerie Johnson; Jonathan Coy; William Wheat; Daniel Regan; Steven Dow Journal: Stem Cells Transl Med Date: 2018-04-10 Impact factor: 6.940